COMPARISON OF AZATHIOPRINE, CYCLOPHOSPHAMIDE, AND GOLD IN TREATMENT OF RHEUMATOID-ARTHRITIS
COMPARISON OF AZATHIOPRINE, CYCLOPHOSPHAMIDE, AND GOLD IN TREATMENT OF RHEUMATOID-ARTHRITIS
复制标题
DOI：
10.1136/bmj.3.5934.763
复制
发表时间：
1974-01-01
影响因子：
105.7
通讯作者：
OWENSMIT.B
中科院分区：
文献类型：
--
作者：
CURREY, HLF;HARRIS, J;OWENSMIT.B
硫唑嘌呤、环磷酰胺和GOLD在双盲条件下治疗相对早期类风湿性关节炎进行了比较。在18个月的时间里，这两种“免疫抑制”药物产生了与GOLD相当的临床改善，它们还促进了皮质类固醇剂量的减少和延缓放射学关节的恶化。硫唑嘌呤的药物管理最容易。环磷酰胺可能是最有效的药物，但它会导致男性无精子症。如果恶性肿瘤和突变的长期危害被证明是可以接受的，那么抗增殖剂提供了一种有用的替代黄金疗法，并可以相对较早地在类风湿性关节炎病程中给予优势。
Azathioprine, cyclophosphamide, and gold have been compared under double-blind conditions in the treatment of relatively early rheumatoid arthritis. Over 18 months the two “immunosuppressive” agents produced clinical improvement comparable to that achieved with gold, and they also facilitated a reduction in the dosage of corticosteroids and retarded radiological joint deterioration. Drug management was easiest with azathioprine. Cyclophosphamide was perhaps marginally the most effective drug but it produced azoospermia in males. If the long-term hazards of malignancy and mutagenesis prove to be acceptable then the anti-proliferative agents provide a useful alternative to gold therapy and can with advantage be given relatively early in the course of rheumatoid arthritis.